ASH 2018 | Subgroup analysis update for the ARROW study: once-weekly carfilzomib for R/R myeloma
VJHemOnc is committed to improving our service to you
Thanks for your feedback, this will help us improve our content for you!
Here, Keith Stewart, MB, ChB, of the Mayo Clinic, Rochester, MN, gives us an update on the subgroup analysis data for the ARROW study (NCT02412878), which compared a once-weekly vs. twice-weekly regimen of carfilzomib in combination with dexamethasone for relapsed/refractory multiple myeloma. This video was recorded at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.
Get great new content delivered to your inboxSign up